Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

DIDANOSINE

DIDANOSINE

Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview DIDANOSINE is listed in Drugs@FDA under application 090788 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DIDANOSINE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 250MG Sponsor PHARMOBEDIENT Submission history Latest submission status date: 2019-12-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview DIDANOSINE is listed in Drugs@FDA under application 090788 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DIDANOSINE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 250MG Sponsor PHARMOBEDIENT Submission history Latest submission status date: 2019-12-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.